Investor Relations

• Publications
• Communication Calendar
• Regulated Information
• Annual financial reports, Half-year financial reports, Quarterly financial information
• Financial-security-law Report of the Chairman of the Board on Corporate Governance and Internal Control
• Fees received by Statutory Auditors
• Total Number of Voting Rights and Shares
• Prospectus Related to Public Offering
• Releases
• General Meeting Preparatory Documents
• Share Repurchase
• Information Published Pursuant to Article 223-21 of the AMF General Regulation
• Breakdown of Capital
• The bioMérieux Share
• Analyst Coverage
• Contacts

Regulated Information

Annual financial reports, Half-year financial reports, Quarterly financial information

Rapport financier semestriel relatif au premier semestre clos le 30 juin 2010 Read More

July 22, 2010 bioMérieux - First-Half 2010 Business Review Sales: €651 million Up 6% at constant exchange rates and scope of consolidation Strong performance of clinical and industrial microbiology as well as VIDAS® Robust growth in emerging countries 2010 operating margin objective confirmed Read More

April 28, 2010 Reference Document 2009 Read More

April 21, 2010 bioMérieux - First Quarter 2010 Business Review Sales up 6.4% at constant exchange rates and scope of consolidation. Read More

March 8, 2010 bioMérieux results 2009 Solid operating and financial performance: Strong growth in sales: up 10.4% - At constant exchange rates Significant increase in operating margin: up 14.1%, at 17.4% of sales   The Board of Directors of bioMérieux, a world leader in the field of in vitro diagnostics, met on Friday, March 5, 2010 to approve the consolidated financial statements for the year ended December 31, 2009. The meeting was chaired by Alain Mérieux and attended by the Statutory Auditors. The financial statements have been audited and the Statutory Auditors are in the process of issuing an unqualified opinion. Read More

March 8, 2010 bioMérieux 2015 A powerful strategic vision for 2010-2015, driven by innovation and international development. Read More

January 22, 2010 2009 Business Review bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for fourth-quarter and full-year 2009. Net sales amounted to €1,223 million in 2009, an increase of 7.7% from the €1,111 million reported in 2008, at constant exchange rates and scope of consolidation (like-for-like). For the fourth quarter alone, net sales amounted to €328 million, compared to €311 million for the prior-year period, up 7.5% like-for-like. Read More

October 20, 2009 bioMérieux - Business Review for the nine months ended September 30, 2009 2009 Nine-Month Sales up 7.8% at constant exchange rates and scope of consolidation up 11.2% at constant exchange rates, including business development agreements Read More

Rapport Financier semestriel Relatif au premier semestre clos le 30 juin 2009 Read More

September 9, 2009 First-Half 2009 Results Growth in sales: 10.3 % - At constant exchange rates, including business development agreements 6.0 % - At constant exchange rates and scope of consolidation Growth in operating results before non-recurring items: 16 % Read More